FDA issues two draft guidances for industry to support the approval of pediatric drug products

PREA and BPCA aim to provide pediatric-specific labeling information for drugs, biological products, and vaccines used in children. PREA gives FDA the authority to require pediatric studies of drugs, biological products, and vaccines under certain circumstances. BPCA provides an incentive of additional marketing exclusivity to sponsors who voluntarily complete pediatric clinical studies as requested by FDA.

“FDA is committed to reducing the substantial lag between approval of a drug for adult use and the approval in children,” said Lynne Yao, M.D., director of the Division of Pediatrics and Maternal Health. “These two documents provide the agency’s current thinking about how industry can comply with PREA and BPCA and, ultimately, help increase the availability and timeliness of safe and effective medicines and vaccines for children in the U.S.”

Additional Resources: